Skip to content
Life Sciences Series C Founded 2014

G + FLAS Life Sciences

Developing gene editing technologies for new drugs and plant-based biopharmaceuticals. It focuses on CRISPR-CasN enzymes and CRISPR gene editing to create innovative solutions in healthcare and agriculture. The offerings include CRISPR genome editing, CRISPR services, and protein synthesis. They are developing new drugs, plant-based biopharmaceuticals, and novel crop varieties enriched with vitamins and nutrients.…

📍 Cheongju-si, South Korea · Life Sciences Platforms and Tools,

Funding snapshot

Last roundSeries C
Amount$12M
Date26 August 2019
Total raised$12M
Team size8

About

Developing gene editing technologies for new drugs and plant-based biopharmaceuticals. It focuses on CRISPR-CasN enzymes and CRISPR gene editing to create innovative solutions in healthcare and agriculture. The offerings include CRISPR genome editing, CRISPR services, and protein synthesis. They are developing new drugs, plant-based biopharmaceuticals, and novel crop varieties enriched with vitamins and nutrients. It utilizes platforms like Cancerase for cancer therapeutics and PDB for plant-bas Founded in 2014, headquartered in Cheongju-si, South Korea. The company has raised $12M at the Series C stage backed by investors including Smile Gate Investment, Chong Kun Dang Pharmaceutical, Alpen Route, ActnerLab, E&Investment. Operating in Life Sciences > Life Sciences Platforms and Tools, Food and Agriculture Tech > Crop Tech.

Business model

Genomics > Enabling Technologies > Technology Platforms > Gene Editing,

Life Sciences Platforms and Tools > Research Services > Diversified,

Crop Tech > Farm Inputs > Plant Breeding > Technology Providers

Institutional investors

Smile Gate Investment Chong Kun Dang Pharmaceutical Alpen Route ActnerLab E&Investment

Latest coverage

No articles yet.

Raising like G + FLAS Life Sciences?

Analyze your pitch deck before your next raise.

Analyze My Deck →